SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1
Document Type: S-1
Date Filed: 2026-02-12
Accession Number: 0001493152-26-006407
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226006407/forms-1.htm

Chunk 32 of 83
Word Count: 1498
Character Count: 10090

Document Content:

“ownership change” as defined in Section 382 of the U.S. Internal Revenue Code of 1986, as amended (the “Code”). An ownership change generally occurs if certain direct or indirect “5- percent shareholders,” as defined in Section 382 of the Code, increase their aggregate percentage ownership of a corporation’s stock by more than 50 percentage points over their lowest percentage ownership at any time during the testing period, which is generally the three-year period preceding any potential ownership change. If a corporation experiences an ownership change, the corporation will be subject to an annual limitation that applies to the amount of pre-ownership change NOLs that may be used to offset post-ownership change. qualify as an emerging growth company and a smaller reporting company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies will make our common stock less attractive to investors.

qualify as an “emerging growth company,” as defined in the JOBS Act. For as long as we remain an emerging growth company,
we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies, including,
but not limited to, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and
exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden
parachute payments not previously approved. We will remain an emerging growth company until the earliest of: (i) the last day of the
first fiscal year in which our annual gross revenues exceed $1.235 billion, (ii) the date on which we first qualify as a large accelerated
filer under the rules of the SEC, (iii) the date on which we have, in any three-year period, issued more than $1.0 billion in non-convertible
debt securities, and (iv) the last day of the fiscal year following the fifth anniversary of the completion of this offering.

are a “smaller reporting company” as defined in Rule 12b-2 under the Exchange Act. We may continue to be a smaller reporting
company until the fiscal year following the determination that our voting and non-voting common stock held by non-affiliates is more
than $250 million measured on the last business day of our second fiscal quarter, or our annual revenues are less than $100 million during
the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700 million measured
on the last business day of our second fiscal quarter.

we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from
certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may
choose to present only the two most recent fiscal years of audited financial statements in our annual report on Form 10-K and, similar
to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. Investors
may find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive
as a result, there may be a less active trading market for our common stock and the market price of our common stock may be adversely
affected and more volatile.

CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS

The
information in this prospectus contains “forward-looking statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. All statements contained in this prospectus other than statements of historical fact, including statements regarding
our future operating results and financial position, our business strategy and plans, market growth, and our objectives for future operations,
are forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other important factors
that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements
expressed or implied by the forward-looking statements.

You
can identify some of these forward-looking statements by words or phrases such as “may,” “will,” “could,”
“would,” “expect,” “anticipate,” “aim,” “estimate,” “intend,”
“plan,” “believe,” “is/are likely to,” “potential,” “project,” “target,”
“continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain
these words. The forward-looking statements in this prospectus are only predictions and are based largely on our current expectations
and projections about future events and financial trends that we reasonably believe may affect our business, financial condition, and
results of operations. Although we believe the expectations reflected in any of our forward-looking statements are reasonable, actual
results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition
and results of operations, as well as any forward-looking statements, are subject to change and inherent risks and uncertainties.

These
forward-looking statements present our estimates and assumptions only as of the date of this prospectus and are subject to several known
and unknown risks, uncertainties, and assumptions. Accordingly, you are cautioned not to place undue reliance on forward-looking statements,
which speak only as of the dates on which they are made. Except as required by applicable law, we do not plan to publicly update or revise
any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise.
Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are
not limited to, those summarized below:

●	failure
to obtain FDA approval to commercially sell our product candidates in a timely manner or at all;

●	failure
to carry out our trials on the timelines expected and with the expected efficacy or safety results;

●	whether
heart failure specialists, surgeons and patients in our target markets accept our product candidates, if approved;

●	the
expected growth of our business and our operations, and the capital resources needed to progress our business plan;

●	failure
to scale up of the manufacturing process of our product candidates in a timely manner, or at all;

●	failure
to manufacture our product candidates at a competitive price;

●	our
ability to retain and recruit key personnel, including the development of a sales and marketing infrastructure;

●	reliance
on third party suppliers for certain components of our product candidates;

●	reliance
on third parties to commercialize and distribute our product candidates in the United States and internationally;

●	changes
in external competitive market factors;

●	uncertainties
in generating sustained revenue or achieving profitability

●	unanticipated
working capital or other cash requirements;

●	changes
in FDA regulations, including testing procedures, of medical devices and related promotional and marketing activities;

●	our
estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for, or ability to obtain, additional
financing;

●	estimates of our addressable market, market growth,
future revenue, expenses, capital requirements and our needs for additional financing;

●	our
ability to obtain and maintain intellectual property protection for our product candidates; and

●	changes
in our business strategy or an inability to execute our strategy due to unanticipated changes in the medical device industry.

The
foregoing does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein or
risk factors that we are faced with. Forward-looking statements necessarily involve risks and uncertainties, and our actual results could
differ materially from those anticipated in the forward-looking statements due to a number of factors, including those set forth above
under “Risk Factors” and elsewhere in this prospectus. All subsequent written and oral forward-looking statements
attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained above
and throughout this prospectus. Prior to investing in our common stock, you should read this prospectus and the documents we have filed
as exhibits to the registration statement, of which this prospectus is a part, completely and with the understanding that our actual
future results may be materially different from what we currently expect.

USE
OF PROCEEDS

estimate that we will receive net proceeds from this offering of approximately $       million (or approximately $        million if the underwriters
exercise their over-allotment option in full), after deducting estimated offering expenses payable by us, and based upon an assumed initial
public offering price of $        per share, the midpoint of the estimated price range set forth on the cover page of this prospectus.

intend to use the net proceeds from this offering as follows:

●	approximately
$           (or approximately $      million if the underwriters
exercise their over-allotment option in full), or approximately 60% of the net proceeds from this offering, to fund the RELIVE
Trial and the associated manufacturing activities required to support such trial; and

●	approximately
$           (or approximately $      million if the underwriters
exercise their over-allotment option in full), or approximately 40% of the net proceeds from this offering, for working capital
and other general corporate purposes, including regulatory compliance, intellectual property protection, additional employee hires
and additional contractor retainment.